CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of …
Tag Archives: allergan
November, 2018
October, 2018
-
5 October
Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease
DUBLIN, Oct. 5, 2018 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn’s disease) and EXPEDITION (ulcerative colitis), will evaluate the safety and efficacy of brazikumab and will investigate the role of biomarkers …
August, 2018
-
7 August
Allergan and Editas Medicine to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
DUBLIN, Ireland and CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize …
July, 2018
-
19 July
Allergan and Molecular Partners Announce Positive Results from Two Phase 3 Trials of Abicipar Pegol for Age-Related Macular Degeneration
DUBLIN, July 19, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced the release of two positive clinical trials, SEQUOIA and CEDAR for abicipar, demonstrating that both the 8-week and 12-week …
November, 2017
-
14 November
Allergan’s Vraylar Receives FDA Approval for Use in the Maintenance Treatment of Schizophrenia
DUBLIN, Nov. 13, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment …
September, 2017
-
15 September
FDA Approves Amgen and Allergan’s Mvasi for the Treatment of Five Types of Cancer
THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI is …
June, 2017
-
7 June
FDA Advisory Committee to Review Amgen and Allergan’s Biosimilar Candidate to Bevacizumab
THOUSAND OAKS, Calif., June 7, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab), …
March, 2017
-
15 March
Allergan and Editas Announce CRISPR-Based Research and Development Deal for Rare Eye Diseases
DUBLIN and CAMBRIDGE, Mass., March 14, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance …
December, 2016
-
20 December
Allergan to Acquire Acelity L.P. Inc.’s LifeCell Corporation for $2.9 Billion
DUBLIN, Dec. 20, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, and Acelity today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments. The acquisition …
November, 2016
-
23 November
Allergan Expands CNS Portfolio with Acquisition of Chase Pharmaceuticals
DUBLIN, Nov. 22, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has completed the acquisition of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the development of improved treatments for neurodegenerative disorders including Alzheimer’s disease (AD), Allergan acquired Chase for an …